When Should Changes to Australian Medical Device Registration Be Reported?

Key Points

The timing for reporting changes to Australian medical device registration depends on the impact on product safety, performance, or intended purpose. According to TGA regulations, any change that may affect product safety, quality, or effectiveness, or involve significant modifications to labeling, instructions for use, manufacturing process, raw materials, design, intended use, sterilization method, storage conditions, shelf life, or post-market surveillance data, requires submitting a change application to the TGA before implementation.

Companies should first determine whether the change is major or minor. A change is considered major if it could cause the product to no longer meet the original registration safety or performance standards, require an update to the risk assessment document, or affect clinical evaluation conclusions. Examples include replacing critical raw materials, changing sterilization parameters, adding new intended uses, or modifying warnings or precautions on labels. Minor changes, such as updating a manufacturer's address, correcting spelling errors, or insignificant packaging changes that do not affect safety, typically only need to be notified to the TGA in the annual report or at the next update, but records must be kept.

Companies should establish a change management procedure in accordance with ISO 13485 and MDSAP requirements to classify and evaluate changes and maintain an evidence chain. When submitting a change application, the following documents are required: technical file gap analysis, updated risk management report, clinical evaluation supplement (if applicable), label and instruction for use comparison, and a confirmation letter from the local sponsor. Common risks include: failure to report changes in time leading to suspension or cancellation of product registration; misclassifying a major change as minor and avoiding reporting, resulting in penalties upon audit; and failing to update the post-market surveillance plan after changes. It is recommended that companies consult professional regulatory advisors before making changes, especially for multinational registrations, where core technical files can be reused but must be localized to Australian requirements.

Applicable Scenarios and Core Issue

The Therapeutic Goods Administration (TGA) requirements for reporting changes to medical device registration are risk-based. The core question is whether the change affects the safety, quality, or performance of the product. According to the Medical Devices Regulations 2002, any modification to the design, manufacturing, labeling, intended use, sterilization, or packaging of a registered device must be assessed to determine if it is a major change. Major changes require TGA approval before implementation; non-major changes can be reported in the annual report or at the next update. The trigger for change usually comes from product lifecycle improvements, complaint feedback, regulatory updates, or supply chain adjustments, such as supplier changes, software version upgrades, or changes in clinical indications. The key is whether the change alters the original risk-benefit balance during registration.

Companies should establish a systematic change management process that includes change identification, risk classification, evidence preparation, and submission decision. This process must be integrated with the quality management system (e.g., ISO 13485) and all evaluation records retained. For products with CE, FDA, or MDSAP certifications, note that definitions of changes may differ among regulatory bodies, but TGA rules are stricter, often considering many changes as major.

Registration Judgment Logic

Step-by-step Assessment

• Step 1: Determine if the product remains within TGA regulatory scope. If the change makes the device fall outside the medical device definition (e.g., becoming a drug or biological), reclassification and new registration are needed.
• Step 2: Assess the risk classification of the product. For low-risk Class I devices, most changes may not be considered major, but labels and instructions must remain accurate. For Class IIa, IIb, III, and Active Implantable devices, any change involving materials, design, sterilization, or intended use usually requires reporting.
• Step 3: Analyze the specific nature of the change. List the changes and compare with the original registration technical files to determine if they affect biocompatibility, electrical safety, software validation, clinical evaluation, risk management report, label or instructions, shelf life, storage conditions, etc. If any aspect is affected, it favors classification as a major change.
• Step 4: Consider reuse of existing documentation. If technical files were prepared for NMPA, CE, or FDA, relevant parts can be extracted but must be verified against TGA-specific requirements (e.g., TGA requires risk management per ISO 14971, clinical evaluation per TGA guidance).
• Step 5: Confirm the responsibilities of the local sponsor. Change applications must be submitted by the Australian sponsor, who is responsible for the accuracy of the submission. Companies must closely collaborate with the sponsor to ensure timely communication.

Documentation and Evidence

When submitting a change application, the following core documents are required:

• Change description document: details of change content, reason, and expected impact.
• Technical file gap analysis: comparison between old and new versions, including design drawings, material specifications, software architecture, etc.
• Updated risk management report: re-evaluate risks per ISO 14971, with control measures for new risks.
• Clinical evaluation supplement: if the change affects clinical safety or effectiveness, provide new literature review or clinical trial data.
• Label and instruction for use samples: mark changed parts with revision explanations.
• Performance verification reports: such as new sterilization validation, packaging validation, shelf-life accelerated aging tests.
• Quality system documents: evidence that the change was reviewed and approved per ISO 13485 procedures.
• Sponsor declaration: confirming completeness of change documentation and agreement to assume regulatory obligations.

All documents must be submitted in English and structured per TGA requirements. For multinational registrations, a unified technical document library is recommended, but Australia-specific requirements (e.g., RCM marking, ARTG number inclusion) must be handled separately.

Common Mistakes

• Misclassifying a major change as minor, leading to implementation without approval, which may result in registration cancellation upon TGA detection.
• Updating the product without updating risk management and clinical evaluation documents, causing a broken evidence chain.
• Relying on CE or FDA change approvals, assuming TGA automatically accepts them, whereas TGA requires independent assessment.
• Neglecting label text details: e.g., adding Chinese instructions without updating English labels, or warnings not conforming to TGA format.
• Insufficient communication with the local sponsor, delaying submission due to missing documents.
• Failing to update the post-market surveillance plan after changes, affecting subsequent conformity assessment.

Company Preparation Checklist

• Check whether the change is included in the quality management system change control procedure.
• Assess the impact on product safety, performance, and intended use.
• Compare with TGA's definition of major changes (refer to TGA Guidance on Changes to Medical Devices).
• Collect relevant evidence: test reports, risk assessments, clinical data, etc.
• Confirm consistency of local sponsor information and notify the sponsor to prepare for submission.
• Develop a change implementation timeline, allowing for TGA review period (usually 60–90 working days).
• Prepare a complete change application package including cover letter, forms, and technical documents.
• Retain pre-change version documents for future audits or recalls.

AIMEILI Perspective

From a regulatory consulting perspective, Australian registration changes are one of the most error-prone areas for companies. Many companies underestimate TGA strictness due to leniency in other markets. We recommend: first, establish a comprehensive change management SOP early in the project and embed TGA requirements. Second, conduct formal risk assessments for all changes, regardless of size, and maintain written records. Third, core technical documents (e.g., risk management and clinical evaluation) can be reused but must be localized for TGA, especially applicable standards (e.g., AS/NZS 3200 series) and labeling requirements (including Chinese warning text). Fourth, the local sponsor is not merely a transmitter but a co-responsible party; choose an experienced sponsor and agree on documentation preparation before changes. Fifth, for multinational registrations, use modular technical files with separate change versions for each country to avoid confusion. Finally, certificate control after changes and renewal timelines are equally important; after change approval, check whether the ARTG validity period needs adjustment. By following these methods, companies can significantly reduce the risk of rework and corrections, ensuring maintained registration validity.

Frequently Asked Questions

Q1: How long after a change is implemented must it be reported to the TGA?

For a major change, approval must be obtained from the TGA before implementation. For a non-major change, the TGA recommends updating the record via TGA Business Services within 30 days of the change or at the next annual report. To be safe, regardless of nature, companies should notify their sponsor and prepare documentation immediately after the change to avoid omissions.

Q2: How to remediate if a change was misjudged and not reported?

Cease use of the changed product immediately (recall if already on market), contact the TGA to explain the situation, and submit a change application with an explanation letter. The TGA may issue warnings, fines, or cancel registration depending on circumstances. Prompt cooperation and hiring a regulatory consultant to assist communication are recommended.

Q3: How to report changes for multiple products sharing the same core design?

If the change is global (e.g., raw material change), submit a change application for each affected ARTG entry. However, applications can be bundled by selecting multiple product numbers in the form and providing one common technical file. Note: if different local sponsors exist, signatures from each sponsor are required.

Q4: What are the different rules for software changes?

Software changes (e.g., version upgrades, bug fixes) must be classified by risk. TGA categorizes software changes into: corrective maintenance (usually no reporting), adaptive maintenance (may require reporting), and perfective maintenance (usually major change required). Changes that add new features almost certainly require reporting. Refer to TGA's Software as a Medical Device guidance.